The integrity of the vascular system is fundamental to overall health, supplying oxygen and nutrients to every tissue in the body. When blood vessels are damaged—whether through injury, chronic disease such as atherosclerosis, or surgical interventions—the body initiates a complex repair cascade. Central to this process are growth factors, a diverse group of naturally occurring signaling proteins. These molecules orchestrate cellular behaviors that are critical for vascular tissue repair and the formation of new blood vessels, a process known as angiogenesis. Understanding how growth factors function in this context not only illuminates basic biology but also opens avenues for advanced therapeutic interventions aimed at restoring blood flow to ischemic tissues, accelerating wound healing, and engineering functional vascular grafts. This article explores the specific roles of key growth factors, their mechanisms of action, current clinical applications, associated challenges, and promising future directions.

Understanding Growth Factors

Growth factors are potent signaling molecules that bind to specific transmembrane receptors on target cells. Upon binding, they initiate intracellular signaling cascades that modulate gene expression, leading to changes in cell behavior such as proliferation, migration, differentiation, and survival. Unlike hormones, which often act over long distances, growth factors typically function in a paracrine (local) or autocrine (self-directed) manner. In vascular biology, growth factors are produced by a variety of cell types, including platelets, endothelial cells, smooth muscle cells, and immune cells, especially in response to injury. Their precise spatial and temporal regulation is crucial; too little activity results in failed healing, while excessive or uncontrolled signaling can contribute to pathological conditions like tumor angiogenesis or fibrotic diseases.

Key Growth Factors in Vascular Repair

Several growth factors have been identified as pivotal drivers of vascular repair and angiogenesis. Each plays a distinct but often overlapping role in the sequence of events that lead to functional vessel restoration.

Vascular Endothelial Growth Factor (VEGF)

VEGF is arguably the most critical regulator of angiogenesis. It primarily targets endothelial cells lining blood vessels. Through binding to VEGF receptors (VEGFR-1 and VEGFR-2), it stimulates endothelial cell proliferation, migration, and survival. VEGF also increases vascular permeability, which is essential for allowing plasma proteins to form a provisional scaffold for new vessel growth. During repair, VEGF expression is upregulated by hypoxia (low oxygen) via the hypoxia-inducible factor (HIF) pathway. Without adequate VEGF, endothelial cells fail to form new capillary sprouts, and existing vessels may regress. Clinically, recombinant VEGF has been explored to promote revascularization in ischemic heart disease and peripheral artery disease, though results have been mixed due to delivery challenges. A 2016 review in Nature Reviews Drug Discovery highlights both the promise and the hurdles of VEGF-based therapies.

Platelet-Derived Growth Factor (PDGF)

PDGF is synthesized and released by platelets upon activation at wound sites, making it one of the earliest signals in vascular repair. This growth factor is a potent chemoattractant and mitogen for mesenchymal cells, including pericytes and vascular smooth muscle cells. PDGF recruits these cells to nascent vessels, where they provide structural support and stability. Without PDGF signaling, newly formed capillaries remain fragile and prone to regression, leading to immature and leaky vascular networks. PDGF exists as dimeric isoforms (PDGF-AA, -AB, -BB, etc.) that bind to PDGFR-α and PDGFR-β receptors. The PDGF-BB isoform is particularly important for pericyte recruitment. Recombinant PDGF-BB (becaplermin) is approved for the treatment of diabetic foot ulcers, where it stimulates granulation tissue formation and enhances closure. A 2020 systematic review in Advances in Wound Care confirms its efficacy in chronic wounds.

Basic Fibroblast Growth Factor (bFGF or FGF-2)

bFGF belongs to the fibroblast growth factor family and exerts broad effects on both endothelial cells and smooth muscle cells. It promotes proliferation, migration, and protease production, facilitating the breakdown of extracellular matrix to allow endothelial sprouting. bFGF also stimulates the formation of granulation tissue and supports the survival of vascular cells under stress. Importantly, bFGF acts synergistically with VEGF; co-administration in preclinical models enhances angiogenesis more robustly than either factor alone. However, bFGF's lack of a signal peptide means its release often occurs through cell damage or unconventional secretion pathways, which can complicate therapeutic dosing. Studies have shown that bFGF-coated stents promote re-endothelialization and reduce restenosis. Research reported in Biomaterials in 2017 demonstrates that bFGF-eluting hydrogels accelerate vascular repair in ischemic limbs.

Transforming Growth Factor-β (TGF-β)

TGF-β is a multifunctional cytokine with complex roles in vascular repair. It is produced by platelets, endothelial cells, and macrophages. TGF-β modulates inflammation, stimulates extracellular matrix production by fibroblasts and smooth muscle cells, and regulates endothelial cell phenotype. Depending on the context, TGF-β can promote or inhibit angiogenesis. It induces smooth muscle cell differentiation and vessel maturation, but excessive TGF-β signaling leads to fibrosis and pathological remodeling. In the early stages of repair, TGF-β helps to scaffold the injury site; later, it limits uncontrolled angiogenesis. Targeting TGF-β therapeutically requires careful balancing, as blockade may impair vessel maturation while overactivation may cause tissue fibrosis.

Hepatocyte Growth Factor (HGF)

HGF is a pleiotropic growth factor that binds to the c-Met receptor. In vascular repair, HGF stimulates endothelial cell migration and tube formation, promotes survival, and reduces apoptotic cell death. HGF is particularly effective at inducing angiogenesis in ischemic tissues, including the heart and skeletal muscle. Its actions complement those of VEGF and bFGF, and it may be less prone to inducing vascular permeability and edema. Clinical trials have explored HGF gene therapy for peripheral artery disease with promising safety and efficacy signals. A 2022 phase II trial in Circulation Research reported improved leg perfusion and reduced pain in patients treated with HGF plasmid.

Mechanisms of Action: Signaling Pathways in Vascular Cells

The effects of growth factors are mediated through specific receptor tyrosine kinases (RTKs) or serine/threonine kinase receptors. Upon ligand binding, receptors dimerize and autophosphorylate, recruiting adaptor proteins that activate downstream cascades. Key pathways include the Ras/MAPK pathway, which drives cell proliferation, and the PI3K/Akt pathway, which promotes survival and migration. In endothelial cells, VEGF binding to VEGFR-2 triggers phospholipase C-γ (PLCγ) and protein kinase C (PKC) activation leading to NO production and vasodilation. Simultaneously, activation of the PI3K/Akt pathway upregulates eNOS and increases vascular permeability.

PDGF receptors recruit Src family kinases and activate Ras, which feeds into MAPK signaling. This causes pericyte and smooth muscle cell migration toward the stimulus. bFGF signaling involves FGF receptors (FGFRs) and the docking protein FRS2, which activates both MAPK and PI3K pathways. TGF-β uses a distinct mechanism: it binds to type II receptors that recruit and phosphorylate type I receptors, which then phosphorylate Smad2 and Smad3 transcription factors. These Smad complexes translocate to the nucleus and regulate gene expression important for matrix deposition and vessel maturation.

These pathways do not operate in isolation. Cross-talk occurs at multiple levels. For example, VEGF and bFGF synergize through MAPK amplification, and TGF-β can indirectly modulate VEGF expression via hypoxia-inducible factors. Understanding these interactions is crucial for designing combination therapies that mimic the natural repair environment.

Clinical Applications and Therapeutic Potential

The therapeutic use of growth factors has been explored across a spectrum of vascular pathologies. Here we discuss some of the most clinically advanced applications.

Ischemic Heart Disease

In patients with severe coronary artery disease not amenable to revascularization (i.e., "no-option" patients), therapeutic angiogenesis using growth factors aims to stimulate collateral vessel growth. Trials have investigated intramyocardial injection of VEGF and FGF proteins or gene transfer using adenoviral/plasmid vectors. Meta-analyses show modest improvements in exercise capacity and perfusion, but inconsistent outcomes due to short half-lives, poor retention, and suboptimal dosing. Controlled-release formulations and combination strategies are under investigation.

Peripheral Artery Disease (PAD) and Critical Limb Ischemia

PAD leads to leg pain and can progress to non-healing ulcers and gangrene. Growth factor therapy here has been tested extensively. Recombinant PDGF-BB (becaplermin) is FDA-approved for diabetic foot ulcers. For PAD with claudication, intramuscular injections of HGF or FGF plasmids have been shown to improve ankle-brachial index and walking distance. The phase III STAND trial of HGF gene therapy met its primary endpoint in safety and showed a trend toward reduced amputation rates.

Wound Healing and Chronic Ulcers

Chronic wounds, especially diabetic foot ulcers, venous leg ulcers, and pressure sores, often exhibit deficient growth factor signaling. Topical application of recombinant PDGF-BB stimulates granulation tissue. More sophisticated approaches include growth factor-impregnated dressings (e.g., collagen-based scaffolds loaded with bFGF) and platelet-rich plasma (PRP) therapies, which harness endogenous growth factors from the patient's own blood. PRP contains a cocktail of PDGF, VEGF, TGF-β, and EGF, offering a multi-factor approach that may be more physiologically relevant. A 2021 meta-analysis in Elife found that PRP significantly reduced ulcer size compared to standard care.

Tissue Engineering and Vascular Grafts

Prevascularization of engineered constructs is a major hurdle. Growth factors are incorporated into scaffolds to recruit host cells and promote vessel ingrowth. VEGF is used to pull in endothelial cells, while PDGF stabilizes vessels. Time-controlled delivery, e.g., sequential release of VEGF followed by PDGF, better mimics natural angiogenesis and results in more mature vascular networks. Current research focuses on decellularized scaffolds, 3D bioprinted hydrogels, and stem cell-derived vascular smooth muscle cells—all reliant on precise growth factor presentation.

Challenges in Growth Factor Therapy

Despite robust preclinical data, clinical translation has been slower than anticipated. Several obstacles persist.

Short half-life and poor stability: Most growth factors degrade rapidly in vivo, requiring repeated high-dose injections or continuous infusion, which is impractical and costly. Controlled-release systems using microspheres, hydrogels, or nanoparticles are being developed but have not fully solved retention issues.

Dose-dependent adverse effects: High doses of VEGF can cause hypotension, edema, and even stimulate pathological angiogenesis such as tumor growth or retinopathy. PDGF overstimulation may lead to fibrotic responses. Clinical safety requires careful dose-finding and local delivery to minimize systemic exposure.

Insufficient spatiotemporal control: Angiogenesis is a highly ordered sequence of events. Simultaneous or sustained delivery of a single factor can lead to unstable, leaky vessels or insufficient maturation. Multi-factor delivery with timed release is more effective but technologically complex.

Patient heterogeneity: Many patients who need growth factor therapy have comorbidities (diabetes, chronic kidney disease, advanced age) that impair their endogenous responsiveness. For instance, diabetic tissues often show resistance to VEGF signaling. Therapies may need to be combined with drugs that improve sensitivity or bypass downstream defects.

Tumorigenic risk: Growth factors that promote cell proliferation inevitably raise concerns about cancer. Although no definitive increase in cancer incidence has been reported in clinical trials of angiogenic factors for ischemic disease, long-term surveillance is limited. Using factors like HGF, which has lower mitogenic activity, may be safer.

Future Directions

Research continues to refine growth factor therapies, aiming to overcome current limitations and unlock their full potential.

Targeted delivery systems: Biomaterials that release growth factors in response to specific cues (e.g., matrix metalloproteinase activity, pH changes, or hypoxia) are under development. Injectable hydrogels that form in situ and degrade over weeks allow minimally invasive delivery with sustained release. Nanoparticles conjugated to endothelial-specific antibodies could home to injured vessels, minimizing off-target effects.

Gene therapy and cell engineering: Rather than delivering protein, viral vectors or non-viral plasmids can be used to drive local, sustained expression of growth factors. This reduces the need for repeated dosing. CRISPR-based gene editing may enable permanent modification of vascular cells to overexpress beneficial factors. Ex vivo transduction of mesenchymal stem cells or endothelial progenitor cells with growth factor genes, then transplantation, represents a next-generation approach.

Combination with other modalities: Growth factor therapy is unlikely to be a standalone solution. Combining with exercise, hyperbaric oxygen, or pharmacologic agents (e.g., statins, ACE inhibitors) may improve outcomes. For example, statins upregulate eNOS and improve endothelial function, potentially synergizing with VEGF.

Synthetic analogs and peptidomimetics: Small molecules or peptides that activate growth factor receptors with high specificity and longer half-lives are an active area of drug discovery. Such agents could be orally bioavailable, radically simplifying treatment. Already, non-peptide agonists of the VEGF receptor have shown preclinical promise.

Decoding the angiogenic code: Systems biology approaches, including single-cell RNA sequencing and proteomics, are mapping the full molecular choreography of vascular repair. This may reveal new targets and optimal temporal combinations of factors, moving beyond the handful of molecules currently used.

In conclusion, growth factors are indispensable conductors of the vascular repair orchestra. From VEGF's initiation of sprouting to PDGF's stabilization of nascent vessels, each factor contributes to a tightly coordinated process. While clinical translation has faced hurdles—delivery, safety, and patient variability—ongoing innovations in biomaterials, gene therapy, and combination strategies are steadily advancing the field. As these challenges are addressed, growth factor therapies hold the potential to transform the treatment of ischemic diseases, chronic wounds, and tissue engineering, restoring vascular health to millions of patients worldwide.